Candel Q2 Loss Widens to $38.9M; Cash Runway Extended to Q1 2028
CADL has more than doubled off its 52-week low of $4.35.
Summary
Candel's Q2 loss widened to $38.9 million on higher R&D and a non-cash warrant charge, but $201.6 million in cash extends runway into Q1 2028. New CCO hire and CEO trading plan modification disclosed.
Key Events · Earnings and Guidance · CADL
-
Q2 Net Loss Widens
Net loss of $38.9 million for Q2 2026, up from $4.8 million a year ago, driven by a $12.3 million non-cash warrant liability fair value loss and higher operating expenses.
-
R&D Spending Surges
Research and development expenses rose 183% to $19.8 million, primarily for aglatimagene clinical trials and manufacturing.
-
Cash Runway Extended
Cash and equivalents of $201.6 million as of June 30, 2026, expected to fund operations into Q1 2028.
-
New Chief Commercial Officer
Mark Sims appointed CCO effective July 6, 2026, with base salary $455,000, target bonus 40%, and option grant of 285,000 shares.
Analysis · CADL · Life Sciences
Candel Therapeutics reported a Q2 net loss of $38.9 million, driven by a $12.3 million non-cash warrant liability fair value loss and a 183% increase in R&D spending to $19.8 million. The company ended the quarter with $201.6 million in cash, which management says funds operations into Q1 2028. The filing also reveals a new Chief Commercial Officer hire and a modified CEO 10b5-1 plan, adding governance context.
At the time of this filing, CADL was trading at $10.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $782.5M. The 52-week trading range was $4.35 to $11.36. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.